The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback